卡铂或顺铂为主联合化疗方案治疗恶性淋巴瘤疗效分析

Analysis of Treatment for the Patients with Malignant Lymphoma Combined byCarboplatin or Cisplatin

采用卡铂或顺铂为主联合化疗方案治疗３２例恶性淋巴瘤，其中何杰金淋巴瘤（ＨＤ）６例，非何杰金淋巴瘤（ＮＨＬ）２６例。全组ＣＲ１３例（４０．７％），ＰＲ１３例（４０．７％），总有效率８１．４％（２６／３２）。２６例缓解病人的中位缓解期为１０个月（１．５～４８个月）。全组３２例１．３．５年生存率分别为８７．５％（２８／３２）、６２．５％（２０／３２）、４６．９％（１５／３２）。本组结果表明，除对初治病例疗效显著外，对复发病例亦有较好的疗效。

cases with malignant lymphomas( 6 catqes with HD,26 with NHL ) were treated with combined modality prodominated by carboplatin or cisplatin from January 1987 to December 1992.13 cases(40.7%)were CR,13 cases(40.7%)PR, 26 cases(81.4%)were response. The mean remissive time of 26cases was 10 months (1.5-48 months). The 1、3、5 year survival rates were 87.5%(28/32),62.5%(20/32),46.9%(15/32),respectively.This study showed that the treatment was effective not only for the pri-mary but also for the relapsed diseas.